5:32 PM
 | 
Dec 19, 2012
 |  BC Extra  |  Top Story

Oncothyreon plummets on NSCLC data

Oncothyreon Inc. (NASDAQ:ONTY) fell $2.31 (51%) to $2.19 on Wednesday after it and Merck KGaA (Xetra:MRK) said L-BLP25 missed the primary endpoint of improving overall survival vs. placebo in the Phase III START trial to treat unresectable, locally advanced stage III non-small...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >